PTO/SB/08 (09-06)

Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCI
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

	Substitute for form 1449/PTO			Complete if Known		
	INFORMATION DI	SCLO	SURE	Application Number	09/782,721	
STATEMENT BY APPLICANT			CANT	Filing Date	2/12/2001	
Date Submitted: September 10, 2008 (use as many sheets as necessary)			10 2009	First Named Inventor	H. Michael Shepard	
			10, 2000	Art Unit	1623	
			cessary)	Examiner Name	Crane, Lawrence E.	
Sheet	1	of	1	Attorney Docket Number	060925-0402	

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

UNPUBLISHED U.S. PATENT APPLICATION DOCUMENTS						
Examiner Initials*	Cite No.1	U.S. Patent Application Document Serial Number-Kind Code ² (if known)	Filing Date of Cited Document MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	,
	L10	WO 96/07413 A1	03-14-1996	University of Georgia Research Foundation, Inc.		
						F

Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	RlO	BAGSHAWE "Antibody-directed enzyme prodrug therapy: A review," <i>Drug Development Res.</i> (1995) 34 (2):220-230	
	s10	BALZARINI et al. 'Highly Selective Cytostatic Activity of (E)-5-(2-Bromovinyl)-2'-deoxyuridine Derivatives for Murine Mammary Carcinoma (FM3A) Cells Transformed with the Herpes Simplex Virus Type 1 Thymidine Kinase Gene, 'Molecular Pharmacology (1985) 28:581-587	

Examiner /Lawrence Crane/	Date 10/08/2008 Considered	
---------------------------	-------------------------------	--

*EXAMMER: Initial if reference considered, whether or not citation is in conformance with MPEP 603. Draw line through citation of not in conformance and not considered include copy of this form with next communication to applicant. A fapiciant's numerican include copy of this form with next communication to applicant. A fapiciant's numerican include copy of this form with next consummation to applicant, a fapiciant survival using citation designation number of (pleasting 1.3). 4 For Jupanese patent document, by the two-letter code (WIPO Standard ST.3.1). 4 For Jupanese patent document, by the two-letter code (WIPO Standard ST.3.1). 4 For Jupanese patent document, by the two-letter code (WIPO Standard ST.3.1). 4 For Jupanese patent document, by the world of coursent by the appropriate symbols as indicated on the document under WIPO Standard ST.1.61 possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of Information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to

Inter collection of information is required by 3° UP 11 M² and 5° 106. The information is required to obtain or retain a benefit by the public which is to the feat of year to process jum application. Confidentiality is governed by 50° LSO 122 and 30° 10° 114. This collection is estimated to state 2 hours to complete, including gathering, preparing, preparing, and the state of t